Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCCG-TALL-2025 Project
NCT06855810Phase 3Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2025
- Primary completion
- Jun 2030
- Modality
- Fragment-Derived Small Molecules, Nucleic Acid-Directed Small Molecules, Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 3 trial of dasatinib, venetoclax, homoharringtonine in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Mar 2025; status: recruiting.
02
Drugs
dasatinibvenetoclaxhomoharringtonine
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT06855810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855810.